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Performance of a new HBsAg assay 27samples to confirm the linearity and reproducibility of the automatic Architect assay, and find
out the correlation among the Elecsys and two Architect assays. The coefficients of variation
(0.44e9.53%) and R2Z 0.996e1, which were both determined using values obtained from the
automatic Architect assay, showed good reproducibility and linearity. Results of the two Archi-
tect assays demonstrated a feasible correlation (nZ 130 samples; RZ 0.898, p < 0.01). With
regard to subgroups, correlations between the two Architect assays were better in the hepa-
titis B e antigen (HBeAg)-negative group (HBeAg-negative group vs. HBeAg-positive group:
R Z 0.885 vs. R Z 0.865, both p < 0.01) and low HBV DNA group (low DNA group vs. high
DNA group: R Z 0.886 vs. R Z 0.844, both p < 0.01). Significant correlations were also found
between the results of the Elecsys and Architect assays (R > 0.93 in all cases). In conclusion,
the correlation between the automatic and manual dilution Architect assays was feasible,
particularly in the HBeAg-negative and low DNA groups. With lower labor costs and less human
error than the manual version, the Abbott automatic dilution Architect assay provided a good
clinical performance with regard to the HBsAg levels.
Copyright ª 2014, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Despite the availability of an efficient vaccine, hepatitis B
virus (HBV) infection remains a serious health problem
worldwide [1,2]. After decades of HBV infection, liver
cirrhosis develops in 30e40% of infected people, and hep-
atoma develops in 1e5% of cirrhotic patients [3,4]. Several
factors related to the disease progression of HBV infection
have been identified, including age at infection, host im-
mune status, and the level of HBV replication [5].
With regard to HBV replication, the HBV DNA level and
hepatitis B virus surface antigen (HBsAg) level were found
to be potent indicators, which promoted monitoring and
evaluation of diseases [6e9]. Among the hepatitis B e
antigen (HBeAg)-negative patients, a high HBsAg level,
but not a high HBV DNA level, was shown to be the only
viral risk factor associated with hepatocellular carcinoma
[10e13]. The HBsAg level reflects the clinical stage of
liver disease [12,14], and a cirrhotic patient with high
HBsAg levels is at a higher risk of disease progression [8].
For patients undergoing therapy, a rapid decrease in
HBsAg concentration during interferon therapy is associ-
ated with a higher chance of sustained virological
response [15].
Several standardized commercial assays for hepatitis B
surface antigen quantification are currently available.
Abbott Architect HBsAg, a widely used assay introduced by
Abbott Diagnostics (Lake Forest, IL, USA), is used for
enhanced detection of HBsAg and HBsAg mutants compared
with previous assays [16,17]. The Roche Elecsys HBsAg re-
agent kit (shortened as Elecsys) is another widely used
commercial reagent kit developed by Roche Diagnostics
(Basel, Switzerland), which has long provided HBsAg assay
reliability compared with the Abbott Architect HBsAg
assay.
In this study, the Abbott Architect HBsAg reagent kit was
evaluated using an automatic dilution assay platform,
Abbott Architect HBsAg i1000 (shortened as the automatic
Architect assay). By contrast, the manual Architect assay
refers to the Abbott Architect HBsAg reagent kit with amanual dilution assay platform, Abbott Architect HBsAg
i2000. These new reagent kits demonstrate the enhanced
power of the assay to detect HBsAg and HBsAg mutants,
thereby providing enhanced specificity for the detection,
diagnosis, and management of HBV infection [16]. Never-
theless, the manual dilution assay was reported to be
inferior to the automatic dilution assay in terms of
reproducibility.
This study aimed to further investigate the performance
of the automatic and manual Architect assays in terms of
their reproducibility and linearity, as well as their relative
performance in patient subgroups. We also evaluated their
performance and compared these results with those of the
Roche Elecsys reagent kit. Our analyses enabled the
determination of the power and accuracy of the Abbott
Architect HBsAg and Roche Elecsys HBsAg quantitative as-
says. Investigation of the kinetics of the HBsAg level shows
that these quantitative assays will help predict the viral
activities, evaluate the response to antiviral therapy, esti-
mate the prognosis, and ultimately reveal the clinical sig-
nificance of HBsAg.Materials and methods
Patients and sera
Initially, we collected 133 sera samples from 90 HBV-
infected patients at different time points during their
regular follow-up evaluations. The patients showed positive
serum HBV DNA, and the serum HBsAg had been persistently
positive for at least 6 months. In total, 130 samples were
collected from 87 HBV-infected patients for the study,
among which 42 sera samples were assayed using the
Abbott and Roche reagent kits (automatic and manual Ar-
chitect assays, plus Elecsys) and were designated as the
Abbott & Roche group, and 88 sera samples were assayed
using the automatic and manual Abbott Architect assays
and were designated as the Abbott automatic and manual
groups, respectively (Figure S1).
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Chung-Ho Memorial Hospital, Kaohsiung Medical University,
Kaohsiung, Taiwan. Patients with human immunodeficiency
virus, autoimmune hepatitis, alcohol abuse ( 40 g ethanol
consumed per day), or evidence of cirrhosis or hepatocel-
lular carcinoma were excluded.
Sera were removed from clots within 4 hours of collec-
tion and stored at 70C until further use. Alanine amino-
transferase (ALT) levels were measured using a standard
autoanalyzer.
After informed consent was obtained, sera were
collected from the patients or their guardians. The study
was performed according to the ethical guidelines of the
1975 Declaration of Helsinki. The Institutional Review Board
of Chung-Ho Memorial Hospital, Kaohsiung Medical Univer-
sity, approved the study prior to its start.
HBsAg quantification assays
Three methods were used to quantify the HBsAg levels. Two
methods included the automatic and manual Architect as-
says, which used the Abbott Architect HBsAg i1000 and
i2000 assay platforms (Abbott Diagnostics), respectively.
The automatic and manual Architect assays functioned on
the basis of the detection of chemiluminescent micropar-
ticles. Both the Abbott Architect HBsAg i1000 and i2000
assay platforms provided an onboard dilution function,
which automatically prediluted the samples after they
were loaded. The automatic Architect assay was used for
automatic dilution using the i1000 analyzer, and the manual
Architect assay was performed using the i2000 assay. The
detection range recommended by the manufacturer was
from 0 IU/mL to 250 IU/mL. If the sera samples were of
HBsAg titers greater than 250 IU/mL dilution, then either
the automatic or the manual assay was performed. Both the
assaying times were 30 minutes, and an additional 30 mi-
nutes were required for the manual dilution. The time for
automatic dilution was ignored.
In addition, another method used the Roche Elecsys
HBsAg reagent kit with the Cobas e 411 analyzer (Roche
Diagnostics), which was designated as the reference assay.
The Elecsys assay was an electrochemiluminescence
microparticle assay, which measured the concentration of
the antibodyeantigen complexes in a similar manner to the
Architect assays. The Roche Cobas e 411 assay platform also
provided an automatic dilution function. The duration of
the assay was 18 minutes. The analytic measurement range
proposed by the manufacturer was between 5 IU/mL and
13,000 IU/mL, in which the samples were diluted 100-fold
using the automated dilution function.
Linearity of dynamic range
Three selected sera specimens with an HBsAg level >
105 IU/mL, as confirmed using the three HBsAg quantitative
assays, underwent serial 1:10 dilution. Each dilution was
prepared using 0.1 mL of the previous dilution and 0.9 mL of
a standard lacquer thinner. All the dilutions were tested
using the automatic Architect assay to evaluate the line-
arity of the dynamic range, which was assessed by calcu-
lating the R2 value.Reproducibility
An additional nine specimens from the 130 sera samples,
containing low (< 500 IU/mL), medium (500e10,000 IU/
mL), or high (> 10,000 IU/mL) levels of HBsAg, were
measured using the automatic Architect assay. Each spec-
imen was repeatedly tested once per day, for 3 consecutive
days. Next, a coefficient of variation was derived for each
specimen. The reproducibility was assessed on the basis of
the coefficients of variation of the nine samples.
Quantification of HBV DNA
We used the Roche COBAS TaqMan HBV analyzer (Roche
Diagnostics, Indianapolis, IN, USA); a nucleic acid amplifi-
cation test, which correlates well with Abbott RealTime
HBV (RealTime assay) [18], using the automated real-time
polymerase chain reaction assay for the quantification of
HBV DNA, for all 130 samples. The primer used for the
quantification of HBV DNA was a fragment of the S gene of
HBV DNA. The detection limit for quantification ranged
from 20 IU/mL to 1.7  108 IU/mL.
Dilution of sera samples
Dilution, automatic or manual, was performed if, in the
sera samples tested, the HBsAg titers were > 250 IU/mL.
The automatic and manual Architect assays reported,
respectively, 37 (80.4%) and 31 (67.4%) sera samples with
HBsAg > 250 IU/mL in the Abbott auto group and manual
group, and 21 (51.2%) and 30 (73.1%) samples with
HBsAg > 250 IU/mL in the Abbott & Roche group. Among all
the 130 samples, the rate of dilution was similar for the
automatic and manual Architect assays (44.6% vs. 46.9%).
For both the automatic and the manual Architect assay, the
rate of dilution was higher in the HBeAg-positive group
(65.7% and 62.9% vs. 35.8% and 38.2% in the HBeAg-negative
group, for the automatic and manual assays, respectively,).
A significantly higher rate of dilution was also found in the
high HBV DNA groups (80.9% and 74.5% vs. 22.9% and 30.1%
in the HBeAg-negative group, for the automatic and manual
assays, respectively).
Statistical analysis
For the purpose of data analyses using suitable statistical
methods, an HBV DNA titer below the lower detection limit
of 108 IU/mL was deemed as 54 IU/mL. The clinical data
were expressed as the mean  standard deviation after
logarithmic (log10) transformation of the original values.
Pearson’s correlation coefficient (R) was used to analyze
the correlations between the results of the automatic Ar-
chitect, manual Architect, and Elecsys assays. Simple linear
regression (R2) was used to examine the linearity of the
measurements of the automatic Architect assay, in which
three selected sera samples underwent a serial 1:10 dilu-
tion from 10 to 10,000. The coefficient of variation was
applied to test the reproducibility of the automatic Archi-
tect assay. Data processing and analyses were performed
using the SPSS version 18.0 (SPSS Inc., Chicago, IL, USA).
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Basic demographic data
Among the 87 HBV-infected patients (Table 1), the average
age was 42.7 years (range 23e67 years), and males were
predominant. Among all the 130 sera samples, alanine
aminotransferase (ALT) levels were tested in 124 samples,
and 66 samples were within the normal range (40 IU/L).
Furthermore, of the 116 sera samples tested, 30.2% were
HBeAg positive. The HBV DNA titer was determined in all
the 130 sera samples, with 29 sera samples exhibiting a DNA
level greater than the upper limit (1.7  108 IU/mL) and 56
showing a DNA level lower than the detection limit. The
cutoff value of the HBV DNA titer was determined; the high
DNA group consisted of 47 sera samples, demonstrating a
DNA titer of > 5000 IU/mL. In addition, the low DNA group,
which consisted of 83 sera samples, had a DNA titer 
5000 IU/mL.Table 1 Baseline characteristics of 87 chronic hepatitis B
patients with HBsAg levels as assayed using the Abbott and
Roche assays.
Characteristics Abbott all Abbott and
Roche
n (%) n (%)
All patients 87 41
All samples 130 42
Age (y) <40 37 (42.5) 15 (36.6)
40e60 45 (51.7) 23 (56.1)
>60 5 (5.8) 3 (7.3)
Sex Male 62 (71.3) 32 (78)
Female 25 (28.7) 9 (22)
ALTa (IU/L) 40 66 (53.2) 36 (85.7)
>40 58 (46.8) 6 (14.3)
HBeAgb Positive 35 (30.2) 2 (6.1)
Negative 81 (69.8) 31 (93.9)
HBV DNAc Above detection
limitd
29 (22.3) 16 (38.1)
Below detection
limit
56 (43.1) 26 (61.9)
HBV DNA High DNA groupe 47 (36.2) 6 (14.3)
Low DNA group 83 (63.8) 36 (85.7)
ALT Z alanine aminotransferase; HBeAg Z hepatitis B e anti-
gen; HBV Z hepatitis B virus.
a Among the 130 sera samples studied, 124 samples were
tested for the ALT levels.
b HBeAg count was based on the sera sample instead of the
patient number. HBeAg may be repeatedly checked if the sera
sample was repeatedly collected. Two ambiguous values and 12
unchecked sera samples were excluded, and 116 sera samples
were studied.
c Among the 130 sera samples, 72 samples were tested for
HBV DNA levels. The sera samples of the Abbott and Roche
group were all tested for HBV DNA levels.
d The detection limit of the HBV DNA was 108 IU/mL. For
analysis, a HBV DNA below the detection limit was designated as
54 IU/mL.
e The high-DNA group consisted of a sera sample DNA level
that is greater than the cutoff value of 5000 IU/mL.Among the 130 sera samples studied by Abbott assays, 42
samples from 41 HBV-infected patients comprised the
Abbott & Roche group, which provided the tested values
from the Roche and Abbot automatic assays, i.e., Elecsys
and automatic Architect assays (Table 2, fourth column).
All 42 sera sample exhibited ALT, 36 of which were within
the normal range (40 IU/L). In addition 33 sera samples
exhibited HBeAg and were mostly e antigen negative
(HBeAg positive vs. HBeAg negative: 2 vs. 31). Six patients
were in the high HBV DNA group, and 36 patients belonged
to the low HBV DNA group.
Linearity
To examine the linearity of the automatic Architect assay,
we tested three selected sera samples with an HBsAg level
of > 105 IU/mL, in which each underwent a serial 1:10
dilution from 10 to 10,000. The calculated R2 values
ranged from 0.996 to 1 (Figs. 1AeC).
Reproducibility
Reproducibility of the automatic Architect assay was tested
in terms of the coefficient of variation. In total, nine sera
samples generated a coefficient of variation ranging from
0.44% to 9.53%, with a median of 3.75%. The samples were
sorted into three groups according to the mean value of
HBsAg, The median values of the lower, medium, and high
HBsAg groups were 110.4 IU/mL, 719.3 IU/mL, and
19373.4 IU/mL, respectively, and the coefficients of varia-
tion were 5.13%, 5.61%, and 3.1%, respectively.
Correlations between assays
Forty-two sera samples comprised the Abbott & Roche
group, which were measured using all the three assays.
The Abbott & Roche group showed a positive correlation;
their HBsAg levels were assayed using the automatic Ar-
chitect and Elecsys assay (R Z 0.938; Fig. 2A). Similarly, a
positive correlation was found in the Abbott & Roche
group, as measured using the manual Architect and Elecsys
assays (R Z 0.985; Fig. 2B). For all 130 samples assayed
using the automatic and manual Architect assays, there
was a positive correlation between the results (RZ 0.898;
Fig. 3A).
All 130 sera samples were divided into the following
subgroups: HBeAg-positive and -negative groups, and high-
and low-DNA groups. Interestingly, there was a correlation
between the two Architect assays. After the values were
transformed to log10, the correlation was better in the
HBeAg-negative group than in the HBeAg-positive group
(HBeAg-negative vs. HBeAg-positive groups: R Z 0.885 vs.
R Z 0.865, both p < 0.01; Figs. 3B and 3C, respectively).
The correlation between the two Architect assays for the
results of the high HBV DNA (> 5000 IU/mL) group
(R Z 0.844, p < 0.01) and low HBV DNA ( 5000 IU/mL)
group (R Z 0.886, p < 0.01) are illustrated in Figs. 3D and
3E, respectively. A better correlation was found in the low
HBV DNA group (compared with the high DNA level group)
and in the HBeAg-negative group (compared with the
HBeAg-positive group).
Table 2 Hepatitis B virus surface antigen levelsa of the Abbott & Roche group, using 42 sera samples, as tested using the
automatic Architect assay, manual Architect assay, and Elecsys assay.
HBsAg assay (platform) Automatic Architect assay
(Abbott Architect HBsAg i1000)
Manual Architect assay
(Abbott Architect HBsAg i2000)
Elecsys (Roche Cobas e 411)
1st quartile (KIU/mL) 119.3b (43.1)c 240.7b (40.5) 151.3b
2nd quartile (KIU/mL) 256.1 (216.0) 392.1 (224.8) 300.1
3rd quartile (KIU/mL) 1221.8 (1455.9) 1949.7 (1826.2) 1006
IQR 1102.5 (1412.8) 1709 (1785.7) 854.7
HBeAg Z hepatitis B e antigen; HBV Z hepatitis B virus; IQR Z interquartile range.
a The detection limit of the HBV DNA was 0.108 KIU/mL. For analysis, an HBV DNA below the detection limit was designated as
0.054 KIU/mL.
b Values outside of the bracket symbols were generated from 42 sera samples.
c Values inside the bracket symbols were generated from all 130 sera samples, which were assayed using both Abbott analyzers.
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The Abbott Architect HBsAg assays, which demonstrate
enhanced detection of HBsAg mutants, yielded reliable
results and showed a significant correlation with the Roche
Elecsys assay. The correlation between the automatic and
manual Architect assays was better in the HBeAg-negative
and low DNA groups. The Abbott Architect HBsAg assays
should enable optimal monitoring of disease and timely
adaptation of an antiviral therapy for HBV infection.
Discussion
As an endemic viral infection in Taiwan, HBV remains a
major public health issue. To adequately diagnose, treat,
and evaluate a patient’s treatment responses with the aid
of a reliable diagnostic tool are crucial. Thus, the fluctu-
ating HBsAg level discloses the interaction between HBV
and host immune control. Among HBV-infected patients
with a low viral load, serum HBsAg levels help predictFigure 1. Linearity of the Abbott Architect HBsAg (automatic d
(diluted in series from 10 to 10,000; R2Z 1, p < 0.01), (B) R4199
(C) F28262 (diluted in series from 10 to 10,000; R2 Z 0.996, pdisease progression [8]. The level of HBsAg has been pro-
posed as a marker of infected liver mass or the amount of
covalently closed circular DNA (cccDNA), particularly for
treatment-naive patients [11]. HBsAg levels have been
shown to be a steady, reliable marker of chronic HBV car-
riage, which can also be used to evaluate the clinical stage
of liver disease [12,14] and to predict clinical outcomes
[8,19].
For a chronic HBV carrier, the spontaneous clearance of
serum HBsAg is rare, which occurs at a rate of approxi-
mately 0.5e2.3% per year [2,20]. With regard to antiviral
treatment, HBsAg clearance characterizes a sustained
remission of HBV infection [21], and the annual incidence of
hepatocellular carcinoma is reduced by over 80% as HBsAg
clearance is achieved [7]. Among patients with liver
cirrhosis, high HBsAg levels are consistently associated with
a higher risk of development of HBeAg-negative hepatitis
and cirrhosis [8]. In the subgroup of HBeAg-negative car-
riers, serum HBsAg levels help stratify the risk of hepato-
cellular carcinoma [22]. A decrease in HBsAg level was also
associated with both sustained virological response and
clearance of HBsAg [23,24]. For patients undergoingilution) based on randomly chosen serum samples (A) F27412
0 (diluted in series from 10 to 10000; R2Z 1, p < 0.01), and
< 0.01).
Figure 2. (A) Correlation between the Abbott Architect HBsAg (automatic dilution) and Roche Elecsys HBsAg assays. The HBsAg
titer in 42 sera samples was quantified using both methods. The correlation was studied after the HBsAg values were transformed
by log10. Pearson’s correlation coefficient R Z 0.938, p < 0.01. (B) Correlation between the Abbott Architect HBsAg (manual
dilution) and Roche Elecsys HBsAg assays. The HBsAg titer in 42 sera samples was quantified using both methods. The correlation
was studied after the HBsAg values were transformed by log10. Pearson’s correlation coefficient R Z 0.985, p < 0.01.
HBsAg Z hepatitis B virus surface antigen.
Performance of a new HBsAg assay 31therapy, lower baseline HBsAg levels were superior to HBV
cccDNA or serum HBV DNA in predicting virological re-
sponses to peginterferon alfa-2a and/or lamivudine treat-
ment, and a rapid decrease in HBsAg concentration during
interferon therapy is associated with a higher chance of
sustained virological response [15,25]. The serum HBsAg
profile was also shown to be valuable in clinical follow-up
evaluations for hepatitis B- and C-coinfected patients
treated with interferon [26,27].
The Abbott Architect HBsAg provides enhanced detec-
tion of HBsAg and HBsAg mutants compared with previous
assays [16,17], and this study was the first to assess the
reliability of the newly developed Abbott Architect HBsAg
reagent kits, which involved automatic and manual di-
lutions, compared with the conventional Roche Elecsys
HBsAg. Three serially diluted samples (from 10 to
10,000) were analyzed using the same assay, which
showed good linearity. The reproducibility of the Abbott
Architect HBsAg assay with automatic dilution (automatic
Architect assay) was assessed on the basis of the co-
efficients of variation, which yielded feasible results
ranging from 0.44% to 9.53%.
On the basis of the 130 sera samples, the results of the
two Architect immunoassays demonstrated a feasible cor-
relation (R Z 0.898). Correlation of results between these
assays was also assessed in the four subgroups. A better
correlation was found in the HBeAg-negative group
(R Z 0.885, p < 0.01; Fig. 3C) and low HBV DNA group
(R Z 0.886, p < 0.01; Fig. 3E), compared with the HBeAg-
positive group (R Z 0.865, p < 0.01; Fig. 3B) and high DNA
group (R Z 0.844, p < 0.01; Fig. 3D). To the best of our
knowledge, the positive e antigen and high HBV DNA levels
indicated a higher HBsAg titer [11,14]. A higher HBsAg titer,
particularly when the value was > 250 IU/mL, required a
dilution. However, the dilution itself might alter thecorrelation to some extent. HBeAg-negative and low HBV
DNA groups required fewer dilution counts. The rate of
samples requiring dilution, i.e., HBsAg titer > 250 IU/mL, in
the HBeAg-negative group was 38.2%, compared with 62.9%
in the HBeAg-positive group. The rate of samples requiring
dilution in the low HBV DNA group was 30.1%, which was
also lower than that in the high HBV DNA group (74.5%). The
percentage of manual dilution in all 130 sera samples was
46.9%. Reduced necessity for manual dilution might provide
a better correlation when assaying, in terms of the auto-
matic and manual dilutions.
Significant correlations in HBsAg values were also found
between the Roche Elecsys HBsAg and Abbott Architect
HBsAg assays (automatic Architect vs. Elecsys, R Z 0.938;
manual Architect vs. Elecsys, R Z 0.985; automatic Archi-
tect vs. manual Architect, R Z 0.898).
The severity of HBV-related liver disease differs ac-
cording to the HBV genotype/subgenotypes [28]. Thus,
further research may help establish the reliability of the
Architect assays in different groups of HBV genotypes,
thereby revealing the natural course or treatment response
of the HBsAg levels for each HBV genotype.
In conclusion, the results of the Abbott Architect HBsAg
assays (automatic and manual Architect assays) correlated
well with the results of the conventional Roche Elecsys
HBsAg (Elecsys assay) and the Architect HBsAg reagent kit,
which was demonstrated to be reliable in terms of linearity
and reproducibility. The results of the two Architect assays
also correlated well with each other, particularly in the
HBeAg-negative and low HBV DNA groups. A lower demand
for dilution due to lower HBsAg levels in the HBeAg-
negative and low HBV DNA groups might enhance the cor-
relation between the two Architect assays. Among the
HBeAg-negative groups, as previously mentioned, a high
HBsAg level, rather than a high HBV DNA level, was the only
Figure 3. (A) Correlation between the Abbott Architect HBsAg (automatic dilution) and Abbott Architect HBsAg (manual dilution) assays. The HBsAg titer in 130 sera samples was
quantified using both methods. The correlation was studied after the HBsAg values were transformed by log10. Pearson’s correlation coefficient R Z 0.898, p < 0.01. (B) Cor-
relation between the Abbott Architect HBsAg (automatic dilution) and Abbott Architect HBsAg (manual dilution) assay in terms of 35 HBeAg-positive sera samples. The correlation
was studied after the HBsAg values were transformed by log10. Pearson’s correlation coefficient R Z 0.865, p < 0.01. (C) Correlation between the Abbott Architect HBsAg
(automatic dilution) and Abbott Architect HBsAg (manual dilution) assay in terms of 81 HBeAg-negative sera samples. The correlation was studied after the HBsAg values were
transformed by log10. Pearson’s correlation coefficient RZ 0.885, p < 0.01. (D) Correlation between the Abbott Architect HBsAg (automatic dilution) and Abbott Architect HBsAg
(manual dilution) assays in terms of 48 high-HBV-DNA-level sera samples. The correlation was studied after the HBsAg values were transformed by log10. Pearson’s correlation
coefficient RZ 0.844, p < 0.01. (E) Correlation between the Abbott Architect HBsAg (automatic dilution) and Abbott Architect HBsAg (manual dilution) assays in terms of 82 low-
HBV-DNA-level sera samples. The correlation was studied after the HBsAg values were transformed by log10. Pearson’s correlation coefficient R Z 0.886, p < 0.01.
HBeAg Z hepatitis B e antigen; HBsAg Z hepatitis B virus surface antigen.
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Performance of a new HBsAg assay 33viral risk factor associated with hepatocellular carcinoma
[13,29]. The Abbott automatic dilution Architect HBsAg
assay demonstrated enhanced HBsAg mutant detection
power [16,17], and lower labor costs and human error
compared with the manual dilution version, which enabled
optimal disease monitoring and a timely adaptation of
antiviral therapy for HBV infection.Acknowledgments
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